Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient with NSCLC Who Responded to Afatinib
Wenfeng Fang,Jiadi Gan,Yihua Huang,Huaqiang Zhou,Li Zhang
DOI: https://doi.org/10.1016/j.jtho.2019.07.018
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:EGFR tyrosine kinase inhibitors (TKIs) have become a major treatment modality for advanced patients with NSCLC who have EGFR mutations.1Alexander P.B. Wang X.F. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies.Front Med. 2015; 9: 134-138Crossref PubMed Scopus (33) Google Scholar Acquired resistance to EGFR TKIs ultimately develops and approximately half of resistant mechanisms to the first- and second-generation EGFR TKI were associated with EGFR T790M.2Yu H.A. Riely G.J. Lovly C.M. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Clin Cancer Res. 2014; 20: 5898-5907Crossref PubMed Scopus (72) Google Scholar AZD9291 (osimertinib), a third-generation EGFR TKI, has been approved as a standard treatment for EGFR T790M-mutant NSCLC, but acquired resistance inevitably develops after 9 to 13 months.3Mok T.S. Wu Y.L. A M.-J. et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.N Engl J Med. 2017; 376: 629-640Crossref PubMed Scopus (2185) Google Scholar Resistant mechanisms are known to result from secondary mutations in EGFR, bypass or alternative pathway activation, downstream pathway activation, and histologic transformation.4Cross D.A. Ashton S.E. Ghiorghiu S. et al.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Cancer Discov. 2014; 4: 1046-1061Crossref PubMed Scopus (1449) Google Scholar In vitro study has shown that double mutations EGFR L718V and L858R rendered resistance to erlotinib, gefitinib, and osimertinib, but remained sensitive to afatinib.5Liu Y. Li Y. Ou Q. et al.Acquired EGFR L718V mutation mediates resistance to osimertinib in non–small cell lung cancer but retains sensitivity to afatinib.Lung Cancer. 2018; 118: 1-5Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar The clinical effect of afatinib in patients with EGFR L718V/L858R mutations was unclear. Herein, we report the first case in which co-existing EGFR L718V and L858R confer resistance to osimertinib but retain sensitivity to afatinib in a patient with NSCLC. A 45-year-old Chinese male with 10 years of smoking history presented with cough and dyspnea. Computed tomography (CT) scan showed a left lung upper lobe mass with invasion of mediastinal, bilateral supraclavicular and intrapulmonary lymph nodes in May 2016. Pathologic examination of the supraclavicular lymph node confirmed moderate and highly differentiated adenocarcinoma. Amplification refractory mutation system – polymerase chain reaction genomic testing revealed EGFR L858R+. The patient commenced on first-generation EGFR TKI gefitinib (250 mg per day) at June 2016 and tolerated it well. He underwent local resection of cancer in the left upper lobe 2 month later and maintained treatment of gefitinib for 20 months. CT scan revealed multiple right lung and lymph nodes metastases in February 2018, leading to progressive disease. Molecular analysis with circulating tumor DNA next-generation sequencing (Kingmed Diagnostics, Guangzhou, China) identified the emergence of EGFR T790M. Therefore, the patient was started on osimertinib (80 mg per day) at March 2018. Approximately 8 months later, imaging presented increasing lesions in right lung (Fig. 1A). Repeated next-generation sequencing on CT-guided biopsy specimen (lung tissue) identified the emergence of EGFR L718V (variant allele frequency = 82.05%), in conjunction with L858R (c.2573T>G, 90.18%) and EGFR amplification, without T790M mutation. Based on the preclinical studies, the patient received afatinib (40 mg per day) starting on January 8, 2019. CT scans after 1 month of afatinib treatment showed obvious shrinkage in mediastinal lymph nodes, contributing to partial response (Fig. 1B). Partial response was further confirmed at the third month (Fig. 1C). The patient complained of deteriorating headache. Several enhancing foci were observed through cerebral magnetic resonance imaging, evaluated as brain metastases. Therefore, he underwent palliative local brain radiotherapy at a total dose of 40 Gy (in 4-Gy fractions) and received one cycle of bevacizumab (400 mg) for prevention of brain edema. Chest CT 5 months (Fig. 1D) after afatinib commencement showed consistent disease control. The patient continued on the afatinib treatment until now the cutoff day, July 6, 2019, yielding progression-free survival beyond the central nervous system of at least 6 months. No intolerant adverse events exist. To our best knowledge, this is the first case to report acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient with NSCLC who responded to afatinib. Furthermore, our findings highlight the importance of dynamic genetic monitoring to understand resistant mechanisms and tailor precision therapies for better clinical outcomes. This work was financially supported by National Key R&D Program of China (2016YFC0905500, 2016YFC0905503), Chinese National Natural Science Foundation (81772476, 81602005, 81872499, and 81702283), Science and Technology Program of Guangdong (2017B020227001), Science and Technology Program of Guangzhou (201607020031), and the Strategic Priority Research Program of the Chinese Academy of Science (No. XDA 12020101 to J.D.). Drs. Fang and Gan contributed equally to this work.